# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-058356
Filing Date
2025-04-25
Accepted
2025-04-25 08:32:08
Documents
14

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | acrv-20250424.htm iXBRL | DEFA14A | 16791
2 | GRAPHIC | img244011982_0.jpg | GRAPHIC | 39433
3 | GRAPHIC | img244011982_1.jpg | GRAPHIC | 1315214
4 | GRAPHIC | img244011982_2.jpg | GRAPHIC | 288562
| Complete submission text file | 0000950170-25-058356.txt |  | 3724363

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | acrv-20250424.xsd | EX-101.SCH | 7374
16 | EXTRACTED XBRL INSTANCE DOCUMENT | acrv-20250424_htm.xml | XML | 1303

Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41551 | Film No.: 25870123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)